136 related articles for article (PubMed ID: 28386119)
1. Alterations in erythrocyte fatty acid composition in preclinical Alzheimer's disease.
Goozee K; Chatterjee P; James I; Shen K; Sohrabi HR; Asih PR; Dave P; Ball B; ManYan C; Taddei K; Chung R; Garg ML; Martins RN
Sci Rep; 2017 Apr; 7(1):676. PubMed ID: 28386119
[TBL] [Abstract][Full Text] [Related]
2. Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study.
Chatterjee P; Goozee K; Lim CK; James I; Shen K; Jacobs KR; Sohrabi HR; Shah T; Asih PR; Dave P; ManYan C; Taddei K; Lovejoy DB; Chung R; Guillemin GJ; Martins RN
Sci Rep; 2018 May; 8(1):8008. PubMed ID: 29789640
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load.
Goozee K; Chatterjee P; James I; Shen K; Sohrabi HR; Asih PR; Dave P; ManYan C; Taddei K; Ayton SJ; Garg ML; Kwok JB; Bush AI; Chung R; Magnussen JS; Martins RN
Mol Psychiatry; 2018 Aug; 23(8):1807-1812. PubMed ID: 28696433
[TBL] [Abstract][Full Text] [Related]
4. Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load.
Chatterjee P; Mohammadi M; Goozee K; Shah TM; Sohrabi HR; Dias CB; Shen K; Asih PR; Dave P; Pedrini S; Ashton NJ; Hye A; Taddei K; Lovejoy DB; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2020; 76(1):291-301. PubMed ID: 32538848
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
6. Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants.
Chatterjee P; Goozee K; Sohrabi HR; Shen K; Shah T; Asih PR; Dave P; ManYan C; Taddei K; Chung R; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2018; 63(2):479-487. PubMed ID: 29630554
[TBL] [Abstract][Full Text] [Related]
7. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
[TBL] [Abstract][Full Text] [Related]
8. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
9. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
10. Altered whole-brain white matter networks in preclinical Alzheimer's disease.
Fischer FU; Wolf D; Scheurich A; Fellgiebel A;
Neuroimage Clin; 2015; 8():660-6. PubMed ID: 26288751
[TBL] [Abstract][Full Text] [Related]
11. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
[TBL] [Abstract][Full Text] [Related]
12. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.
Vanitallie TB
Metabolism; 2013 Jan; 62 Suppl 1():S30-3. PubMed ID: 23021038
[TBL] [Abstract][Full Text] [Related]
13. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
14. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study.
Xicota L; Ichou F; Lejeune FX; Colsch B; Tenenhaus A; Leroy I; Fontaine G; Lhomme M; Bertin H; Habert MO; Epelbaum S; Dubois B; Mochel F; Potier MC;
EBioMedicine; 2019 Sep; 47():518-528. PubMed ID: 31492558
[TBL] [Abstract][Full Text] [Related]
16. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
17. Physical Activity and Amyloid-β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment.
de Souto Barreto P; Andrieu S; Payoux P; Demougeot L; Rolland Y; Vellas B;
J Am Geriatr Soc; 2015 Aug; 63(8):1634-9. PubMed ID: 26200930
[TBL] [Abstract][Full Text] [Related]
18. An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation.
Rembach A; Watt AD; Wilson WJ; Rainey-Smith S; Ellis KA; Rowe CC; Villemagne VL; Macaulay SL; Bush AI; Martins RN; Ames D; Masters CL; Doecke JD;
J Neuroimmunol; 2014 Aug; 273(1-2):65-71. PubMed ID: 24907904
[TBL] [Abstract][Full Text] [Related]
19. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
